ELX-02, Potential CF Nonsense Mutation Therapy, on FDA Fast Track

ELX-02, Potential CF Nonsense Mutation Therapy, on FDA Fast Track

305511

ELX-02, Potential CF Nonsense Mutation Therapy, on FDA Fast Track

The U.S. Food and Drug Administration (FDA) has given fast track designation to ELX-02, an investigational treatment for people with cystic fibrosis (CF) caused by nonsense mutations. This FDA designation aims to speed the development and regulatory review of potential treatments for serious or life-threatening diseases with an unmet medical need. It gives Eloxx Pharmaceuticals access to more frequent meetings with the FDA during its therapy’s development process, with the overall aim of getting effective therapies to people…

You must be logged in to read/download the full post.